Nebivolol Unifarma

Nebivolol, the active ingredient in Nebivolol Unifarma, is a beta blocker presented as an oral tablet for oral use. It treats hypertension and heart failure in adult patients. GNH USA supplies Nebivolol Unifarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular disease management. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure: improves left‑ventricular ejection fraction and reduces symptoms of fluid overload. - Left ventricular systolic dysfunction: decreases mortality and hospitalisation rates in patients with reduced ejection fraction.

Nebivolol may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or tiredness. - Nasal congestion or rhinorrhoea. - Bradycardia: heart rate below 60 bpm. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Marked hypotension with syncope. - Acute bronchospasm in patients with reactive airway disease. - Allergic reactions such as rash, pruritus, or angio‑edema. - Hepatic enzyme elevations. - Cardiogenic shock in severe heart failure.

Nebivolol should be used with careful clinical monitoring. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Heart rate assessment: observe for bradycardia, especially in patients with conduction disorders. - Asthma or COPD: use with caution due to potential bronchoconstriction. - Discontinuation: avoid abrupt cessation; taper under physician guidance to prevent rebound hypertension. - Renal/hepatic impairment: dose adjustment may be required based on organ function. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Co‑administration with other beta‑blockers: may cause excessive bradycardia or AV block. - Calcium‑channel blockers (verapamil, diltiazem): increase risk of severe bradycardia and hypotension. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): raise nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Non‑selective beta‑agonists (albuterol): may reduce bronchodilator efficacy. - Diuretics (thiazides, loop diuretics): additive hypotensive effect, monitor electrolytes. - ACE inhibitors or ARBs: combined effect on blood pressure may require dose titration.